The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Marianne Tawa,Hallie Jester,Helen Hancock,Abeer Butt,Sophia Yui Kau Fong ,Theresa Davey,David C Fisher,Alison J Moskowitz,David M Weinstock ,Patricia L Myskowski ,Evan Marzouk,Erica B.K Wang,Nivetha Ganesan,Alexandra Bahgat,Youn H Kim,Eric Jacobsen ,Ahmet Doğan ,Michael S Khodadoust ,Neha Mehta–Shah ,William Blouin,Natasha Galasso,Steven M Horwitz

doi:10.1182/blood-2018-99-115241

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Marianne Tawa, Hallie Jester + Show 20 more

Open Access

https://doi.org/10.1182/blood-2018-99-115241

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 30

Affiliation: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Stanford University

#Research Funding #Maximum Tolerated Dose + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Full Text